<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">19568011</PMID>
<DateCompleted>
<Year>2009</Year>
<Month>09</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1539-2570</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>29</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2009 Jul-Aug</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Journal of pediatric orthopedics</Title>
<ISOAbbreviation>J Pediatr Orthop</ISOAbbreviation>
</Journal>
<ArticleTitle>Botulinum toxin type A injection in alleviating postoperative pain and improving quality of life in lower extremity limb lengthening and deformity correction: a pilot study.</ArticleTitle>
<Pagination>
<MedlinePgn>427-34</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/BPO.0b013e3181aad628</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Ilizarov technique is commonly used for lengthening and deformity corrections of the lower limbs in children. Postoperative pain can be significant, affecting quality of life and functional mobility, and often requiring prolonged medication use. Several studies have investigated the antinociceptive actions of botulinum toxin type A (BtX-A), yet evidence for its use in this population is limited. The objectives were to (1) establish the feasibility of a randomized clinical trial in children undergoing limb lengthening or deformity correction and (2) provide preliminary evidence of the beneficial effects of BtX-A in this population.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-two patients with a mean age of 13.7 years (range, 5 to 21 y) were randomized to receive either BtX-A or an equivalent volume of sterile saline solution (placebo group), as a single dose during the surgical procedure. Pain, medication use, quality of life, and functional mobility outcomes were assessed in all patients. Adverse events were reported for all patients and classified as minor or major.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Differences between groups did not reach statistical significance; however, pain at mid-distraction was found to be slightly lower in the BtX-A group, as compared with the placebo group. Patients in the BtX-A group used less parenteral pain medication in the first 4 days after the surgery, had higher quality of life scores at 3 of the 5 time points assessed, and slightly higher functional mobility scores. All adverse events were expected complications of the lengthening process. No event was considered to be a serious adverse event related to the BtX-A injection itself. There was a trend toward fewer major adverse events in the BtX-A group.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This pilot study established the feasibility of a randomized controlled trial design for in this population. Its findings indicate that BtX-A injections appear to be safe and effective for reducing pain and improving the quality of life and functional mobility of children undergoing lengthening or deformity corrections of the lower limbs. A larger-scale study is currently underway to confirm these preliminary findings.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hamdy</LastName>
<ForeName>Reggie C</ForeName>
<Initials>RC</Initials>
<AffiliationInfo>
<Affiliation>Shriners Hospital for Children, Montreal, Quebec, Canada. rhamdy@shriners.mcgill.ca</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Montpetit</LastName>
<ForeName>Kathleen</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Raney</LastName>
<ForeName>Ellen M</ForeName>
<Initials>EM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aiona</LastName>
<ForeName>Michael D</ForeName>
<Initials>MD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fillman</LastName>
<ForeName>Ramona R</ForeName>
<Initials>RR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>MacKenzie</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McCarthy</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chafetz</LastName>
<ForeName>Ross S</ForeName>
<Initials>RS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Thomas</LastName>
<ForeName>Susan Sienko</ForeName>
<Initials>SS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tamayo</LastName>
<ForeName>Cynthia M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Littleton</LastName>
<ForeName>Aaron G</ForeName>
<Initials>AG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ruck-Gibis</LastName>
<ForeName>Joanne</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>Susan N</ForeName>
<Initials>SN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rinaldi</LastName>
<ForeName>Mario</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Finley</LastName>
<ForeName>G Allen</ForeName>
<Initials>GA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Platt</LastName>
<ForeName>Robert W</ForeName>
<Initials>RW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dahan-Oliel</LastName>
<ForeName>No√©mi</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pediatr Orthop</MedlineTA>
<NlmUniqueID>8109053</NlmUniqueID>
<ISSNLinking>0271-6798</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018889">Ilizarov Technique</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007870">Leg Length Inequality</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D035002">Lower Extremity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D038061">Lower Extremity Deformities, Congenital</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009465">Neuromuscular Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010149">Pain, Postoperative</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2009</Year>
<Month>7</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2009</Year>
<Month>7</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2009</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">19568011</ArticleId>
<ArticleId IdType="doi">10.1097/BPO.0b013e3181aad628</ArticleId>
<ArticleId IdType="pii">01241398-200907000-00003</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>